AstraZeneca plc (ADR) (NYSE:AZN) has cash and equivalents of approximately $9 billion, which is much less when compared to Pfizer. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) is also in trouble due to its Copaxone expiry, and has adopted a pretty unique approach to facing this crisis. The company is trying to find new applications for its existing compounds and focusing on expanding its OTC segment.
AstraZeneca is headed in the right direction, but the company will have to take more urgent measures to address its revenue decline. This will not be as easy as acquiring a small high potential bio-pharmaceutical company, because some major players are already on the hunt for promising acquisition targets.
The article This Pharma Company Needs to Take Urgent Measures originally appeared on Fool.com and is written by Mohsin Saeed.